{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:11:42Z","timestamp":1770966702135,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"vor","delay-in-days":3648,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2006]]},"DOI":"10.1111\/j.1469-0691.2006.01403.x","type":"journal-article","created":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T09:30:13Z","timestamp":1141810213000},"page":"11-16","source":"Crossref","is-referenced-by-count":46,"special_numbering":"S2","title":["Can \u03b2-lactams be re-engineered to beat MRSA?"],"prefix":"10.1016","volume":"12","author":[{"given":"D.M.","family":"Livermore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2006.01403.x_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/bmj.1.5219.124-a","article-title":"Celbenin\u2010resistant staphylococci","volume":"i","author":"Jevons","year":"1961","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2006.01403.x_bib2","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1093\/clinids\/24.Supplement_1.S74","article-title":"The progressive intercontinental spread of methicillin\u2010resistant Staphylococcus aureus","volume":"24","author":"Ayliffe","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jac\/48.1.143","article-title":"Dominance of EMRSA\u201015 and \u201016 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS)","volume":"48","author":"Johnson","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib4","author":"Health Protection Agency"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/dki266","article-title":"Surveillance and epidemiology of MRSA bacteraemia in the UK","volume":"56","author":"Johnson","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib6","first-page":"191","article-title":"Epidemic methicillin resistant Staphylococcus aureus","volume":"7","year":"1997","journal-title":"Commun Dis Rep CDR Wkly"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0195-6701(98)90293-6","article-title":"Revised guidelines for the control of methicillin\u2010resistant Staphylococcus aureus infection in hospitals","volume":"39","author":"British Society for Antimicrobial Chemotherapy, Hospital Infection Society","year":"1998","journal-title":"J Hosp Infect"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib8","author":"European Antimicrobial Resistance Surveillance System (EARSS)"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid1009.040069","article-title":"Methicillin\u2010resistant Staphylococcus aureus in Europe, 1999\u20132002","volume":"10","author":"Tiemersma","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728222.8.6.515","article-title":"MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistance","volume":"8","author":"Barrett","year":"2004","journal-title":"Expert Opin Ther Targets"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/32.2.247","article-title":"Multicentre survey of the comparative in\u2010vitro activity of piperacillin\/tazobactam against bacteria from hospitalized patients in the British Isles","volume":"32","author":"Chen","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0924-8579(03)00108-0","article-title":"In vitro activity of piperacillin\/tazobactam and other broad\u2010spectrum antibiotics against bacteria from hospitalised patients in the British Isles","volume":"22","author":"Livermore","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/33.1.7","article-title":"Molecular aspects of methicillin resistance in Staphylococcus aureus","volume":"33","author":"De Lencastre","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib14","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.44.6.1549-1555.2000","article-title":"A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus","volume":"44","author":"Katayama","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1469-0691.2004.00768.x","article-title":"Multilocus sequence typing and the evolution of methicillin\u2010resistant Staphylococcus aureus","volume":"10","author":"Robinson","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib16","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/JCM.43.5.2380-2383.2005","article-title":"Genetic background affects stability of mecA in Staphylococcus aureus","volume":"43","author":"Katayama","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib17","doi-asserted-by":"crossref","first-page":"8821","DOI":"10.1073\/pnas.161098098","article-title":"Evolutionary genomics of Staphylococcus aureus: insights into the origin of methicillin\u2010resistant strains and the toxic shock syndrome epidemic","volume":"98","author":"Fitzgerald","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib18","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1073\/pnas.122108599","article-title":"The evolutionary history of methicillin\u2010resistant Staphylococcus aureus (MRSA)","volume":"99","author":"Enright","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/13543784.12.3.379","article-title":"Novel antibacterial agents for the treatment of serious Gram\u2010positive infections","volume":"12","author":"Abbanat","year":"2003","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00001432-200412000-00007","article-title":"Recent advances in the treatment of infections due to resistant Staphylococcus aureus","volume":"17","author":"Anstead","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib21","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin: analysis of two double\u2010blind studies of patients with methicillin\u2010resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib22","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/313440","article-title":"Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin\u2010resistant and methicillin\u2010susceptible organisms","volume":"29","author":"Gonzalez","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib25","first-page":"870","article-title":"Structural basis for the beta lactam resistance of PBP2a from methicillin\u2010resistant Staphylococcus aureus","volume":"9","author":"Lim","year":"2002","journal-title":"Nat Struct Biol"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0966-842X(03)00046-5","article-title":"Solving staphylococcal resistance to beta\u2010lactams","volume":"11","author":"Chambers","year":"2003","journal-title":"Trends Microbiol"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.2042-7158.1995.tb06731.x","article-title":"The influence of uptake from the gastrointestinal tract and first\u2010pass effect on oral bioavailability of (Z)\u2010alkyloxyimino penicillins","volume":"47","author":"Mizen","year":"1995","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/AAC.39.2.462","article-title":"In vitro and in vivo antistaphylococcal activities of L\u2010695,256, a carbapenem with high affinity for the penicillin\u2010binding protein PBP 2a","volume":"39","author":"Chambers","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/AAC.40.3.795","article-title":"Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin\u2010resistant Staphylococcus aureus","volume":"40","author":"Sundelof","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000239452","article-title":"In vitro antibacterial activity of TOC\u201050, a new parenteral cephalosporin against methicillin\u2010resistant Staphylococcus aureus and Staphylococcus epidermidis","volume":"42","author":"Nomura","year":"1996","journal-title":"Chemotherapy"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1128\/AAC.45.5.1422-1430.2001","article-title":"In vitro activities of RWJ\u201054428 (MC\u201002,479) against multiresistant gram\u2010positive bacteria","volume":"45","author":"Chamberland","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-004-0309-3","article-title":"In vitro antimicrobial activity of T\u201091825, a novel anti\u2010MRSA cephalosporin, and in vivo anti\u2010MRSA activity of its prodrug, TAK\u2010599","volume":"10","author":"Iizawa","year":"2004","journal-title":"J Infect Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib33","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/AAC.49.8.3239-3250.2005","article-title":"In vitro and in vivo antibacterial activities of CS\u2010023 (RO4908463), a novel parenteral carbapenem","volume":"49","author":"Koga","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.45.3.825-836.2001","article-title":"In vitro and in vivo properties of Ro 63\u20109141, a novel broad\u2010spectrum cephalosporin with activity against methicillin\u2010resistant staphylococci","volume":"45","author":"Hebeisen","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1358\/dof.2005.030.01.873914","article-title":"Ceftobiprole\/ceftobiprole medocaril","volume":"30","author":"Sorbera","year":"2005","journal-title":"Drugs Future"},{"key":"10.1111\/j.1469-0691.2006.01403.x_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(05)70112-2","article-title":"Community\u2010acquired methicillin\u2010resistant Staphylococcus aureus: an emerging threat","volume":"5","author":"Zetola","year":"2005","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15602452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15602452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T03:11:01Z","timestamp":1555470661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15602452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":36,"alternative-id":["S1198743X15602452"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01403.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2006]]}}}